| Q50589544 | A Memory B Cell Crossmatch Assay for Quantification of Donor-Specific Memory B Cells in the Peripheral Blood of HLA-Immunized Individuals. |
| Q64067275 | A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation |
| Q37252505 | Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor-Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching |
| Q100408260 | Angiotensin II type 1 receptor antibodies in kidney transplantation: An evidence-based comprehensive review |
| Q51682057 | Anti-Donor HLA Antibody Response After Pancreatic Islet Grafting: Characteristics, Risk Factors, and Impact on Graft Function. |
| Q58718244 | Anti-HLA Donor-Specific IgG Subclasses and C1q-binding Evolution in Posttransplant Monitoring |
| Q28076193 | Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q30277267 | Approach to the Highly Sensitized Kidney Transplant Candidate |
| Q55449985 | B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome. |
| Q39101892 | B Cell Immunity in Solid Organ Transplantation. |
| Q89529172 | C3d-Positive Preformed DSAs Tend to Persist and Result in a Higher Risk of AMR after Kidney Transplants |
| Q64114462 | C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection |
| Q90265882 | CXCR5+PD1+ICOS+ Circulating T Follicular Helpers Are Associated With de novo Donor-Specific Antibodies After Renal Transplantation |
| Q42700183 | Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation. |
| Q51087941 | Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. |
| Q92712461 | Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays |
| Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
| Q40967497 | Chronic rejection: Differences and similarities in various solid organ transplants |
| Q47574733 | Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies |
| Q47147931 | Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies |
| Q33882783 | Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation |
| Q50916067 | Complement Recognition Pathways in Renal Transplantation. |
| Q46970385 | Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment |
| Q54969814 | Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. |
| Q58488462 | Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure |
| Q90061864 | Current Trends in Applications of Circulatory Microchimerism Detection in Transplantation |
| Q34047345 | Current status of alloimmunity |
| Q47839666 | Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury |
| Q64120707 | Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01 |
| Q101038727 | Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation |
| Q47563660 | Desensitisation strategies in high-risk children before kidney transplantation. |
| Q64263915 | Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff |
| Q97518750 | Distribution of de novo Donor-Specific Antibody Subclasses Quantified by Mass Spectrometry: High IgG3 Proportion Is Associated With Antibody-Mediated Rejection Occurrence and Severity |
| Q39265221 | Donor-Specific Antibodies in Kidney Transplant Recipients |
| Q43110440 | Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients |
| Q58733582 | Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients |
| Q60400189 | Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study |
| Q39512442 | Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. |
| Q38731333 | Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. |
| Q89965614 | Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts |
| Q93161825 | Effector and regulatory B cells in immune-mediated kidney disease |
| Q50088087 | Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection. |
| Q51563025 | Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. |
| Q39366464 | Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans |
| Q94588711 | Flow cytometry crossmatching to investigate kidney-biopsy-proven, antibody-mediated rejection in patients who develop de novo donor-specific antibodies |
| Q37590820 | From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. |
| Q37601515 | Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells. |
| Q64069939 | Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes |
| Q42263289 | IL-21 Receptor Antagonist Inhibits Differentiation of B Cells toward Plasmablasts upon Alloantigen Stimulation |
| Q37563822 | IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES. |
| Q38793766 | Immune monitoring in renal transplantation: The search for biomarkers |
| Q92543386 | Impact of Induction Therapy on Circulating T Follicular Helper Cells and Subsequent Donor-Specific Antibody Formation After Kidney Transplant |
| Q47130649 | Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome. |
| Q30381837 | Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein |
| Q47835201 | Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection |
| Q36007256 | Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians |
| Q33842250 | Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study |
| Q89594061 | Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+T cells with De Novo DSA Production in the First Year After Kidney Transplant |
| Q99413308 | Investigating the relationship between class I HLA-specific immunoglobulin-G subclasses, Pan-IgG single antigen bead assays and complement mediated interference in sera from renal transplant recipients |
| Q51585363 | Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. |
| Q50993047 | Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates. |
| Q58559130 | Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies |
| Q38877380 | Molecular assessment of disease states in kidney transplant biopsy samples |
| Q38773711 | Moving Biomarkers toward Clinical Implementation in Kidney Transplantation |
| Q39217968 | Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection |
| Q92525914 | Prognostic value of C3d-fixing, preformed donor-specific antibodies in crossmatch-positive living kidney transplantation |
| Q40330667 | Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study |
| Q92558904 | Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies |
| Q37611251 | Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes? |
| Q41573946 | Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant. |
| Q33760357 | Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies. |
| Q90280242 | Terminally Differentiated Effector Memory CD8+ T Cells Identify Kidney Transplant Recipients at High Risk of Graft Failure |
| Q42174325 | The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. |
| Q28087773 | The Complement System and Antibody-Mediated Transplant Rejection |
| Q30397251 | The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies |
| Q38676925 | The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations |
| Q38960197 | The Road to HLA Antibody Evaluation: Do Not Rely on MFI. |
| Q38558079 | The exciting "bench to bedside" journey of cell therapies for acute kidney injury and renal transplantation |
| Q64105881 | Transplant Glomerulopathy With Glomerular C3 Deposits: Why the Worse Outcome? |
| Q47311433 | Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury. |
| Q89049434 | Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation |
| Q40634986 | Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss |